Orthofix Medical (NASDAQ:OFIX) Issues Quarterly Earnings Results

Orthofix Medical (NASDAQ:OFIX) released its earnings results on Tuesday. The medical device company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.16, FiscalAI reports. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The firm had revenue of $196.71 million during the quarter, compared to analyst estimates of $196.40 million.

Here are the key takeaways from Orthofix Medical’s conference call:

• Company reported a solid start to 2026 with total net sales of $196.4M (up 3% pro forma) and reaffirmed full‑year guidance of $850–860M in net sales and $95–98M adjusted EBITDA, with positive free cash flow expected.
• Management simplified spine leadership and says distributor transitions are largely complete, positioning the business to accelerate as it pushes adoption of the 7D FLASH ecosystem and the full‑market launch of Virada in H2 2026.
• Execution with prioritized partners is driving results — the top 30 U.S. distributors grew net sales 27% YoY (24% on a trailing 12‑month basis), which management highlights as validation of its distributor strategy.
• Biologics remain a weak spot despite sequential improvement; the business was realigned under limb reconstruction leadership and management expects a return to market growth, but it represents a near‑term execution risk.
• Financial and margin trends showed improvement, with pro forma non‑GAAP adjusted gross margin at 70.7% (up 40 bps), Q1 adjusted EBITDA of $9.7M, and a cash balance of $120.9M.

Orthofix Medical Price Performance

OFIX traded down $0.09 on Thursday, reaching $12.10. The company had a trading volume of 327,467 shares, compared to its average volume of 266,658. The company has a fifty day moving average of $12.21 and a 200-day moving average of $13.91. The company has a market capitalization of $485.61 million, a P/E ratio of -8.01 and a beta of 0.79. The company has a current ratio of 2.87, a quick ratio of 1.43 and a debt-to-equity ratio of 0.54. Orthofix Medical has a one year low of $10.24 and a one year high of $16.99.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, insider Lucas Vitale sold 4,269 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $11.92, for a total value of $50,886.48. Following the completion of the sale, the insider directly owned 160,449 shares of the company’s stock, valued at approximately $1,912,552.08. This represents a 2.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jorge Andres Cedron sold 3,743 shares of Orthofix Medical stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $12.82, for a total transaction of $47,985.26. Following the completion of the transaction, the insider owned 59,006 shares in the company, valued at approximately $756,456.92. This trade represents a 5.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.30% of the stock is currently owned by insiders.

Institutional Trading of Orthofix Medical

A number of hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. lifted its stake in Orthofix Medical by 1.5% during the third quarter. Raymond James Financial Inc. now owns 66,812 shares of the medical device company’s stock valued at $978,000 after buying an additional 1,000 shares in the last quarter. Amundi lifted its stake in Orthofix Medical by 2.7% during the fourth quarter. Amundi now owns 41,527 shares of the medical device company’s stock valued at $630,000 after buying an additional 1,086 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Orthofix Medical by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after purchasing an additional 1,213 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Orthofix Medical by 1.9% in the fourth quarter. Deutsche Bank AG now owns 78,962 shares of the medical device company’s stock worth $1,197,000 after purchasing an additional 1,473 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Orthofix Medical by 21.1% in the second quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock worth $166,000 after purchasing an additional 2,589 shares in the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on OFIX. Canaccord Genuity Group reduced their price target on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Stifel Nicolaus reduced their price target on shares of Orthofix Medical from $22.00 to $18.00 and set a “buy” rating for the company in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a report on Tuesday, April 21st. TD Cowen started coverage on shares of Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price target for the company. Finally, Barrington Research reaffirmed an “outperform” rating and set a $17.00 target price on shares of Orthofix Medical in a research note on Friday, April 10th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Orthofix Medical has a consensus rating of “Hold” and a consensus price target of $17.25.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.